Taxpayers and patients lose out over lack of lower cost medicines

Major reform is still needed to pass on savings on medicines to taxpayers and patients.

The Healthcare Enterprise Alliance (HEA) said the Government’s pricing agreement with pharmaceutical manufacturers is failing to deliver the best possible value.

When the agreement was announced last July, the HEA warned that the agreement would restrict the entry of lower cost biosimilar medicines and reduce their uptake.